Swiss National Bank
TVRD

Swiss National Bank’s Tvardi Therapeutics TVRD Stock Holding History

Swiss National Bank’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,739
Closed -$484K – 2668
2023
Q1 		$484K Sell
2,739
-322
-11% -$108K ﹤0.01% 2532
2022
Q4 		$1.18M Buy
3,061
+61
+2% +$23.2K ﹤0.01% 2256
2022
Q3 		$1.01M Buy
3,000
+53
+2% +$19.2K ﹤0.01% 2333
2022
Q2 		$969K Buy
2,947
+139
+5% +$48.8K ﹤0.01% 2386
2022
Q1 		$1.23M Buy
2,808
+364
+15% +$149K ﹤0.01% 2307
2021
Q4 		$1.07M Hold
2,444
– – ﹤0.01% 2440
2021
Q3 		$1.36M Hold
2,444
– – ﹤0.01% 2276
2021
Q2 		$1.26M Sell
2,444
-562
-19% -$356K ﹤0.01% 2370
2021
Q1 		$2.35M Buy
3,006
+206
+7% +$141K ﹤0.01% 1907
2020
Q4 		$1.52M Hold
2,800
– – ﹤0.01% 2066
2020
Q3 		$1.28M Buy
2,800
+50
+2% +$29K ﹤0.01% 1944
2020
Q2 		$1.69M Buy
2,750
+486
+21% +$268K ﹤0.01% 1806
2020
Q1 		$1.08M Buy
2,264
+36
+2% +$19.6K ﹤0.01% 1790
2019
Q4 		$1.29M Buy
2,228
+103
+5% +$72.3K ﹤0.01% 1991
2019
Q3 		$1.4M Buy
2,125
+292
+16% +$243K ﹤0.01% 1873
2019
Q2 		$1.42M Buy
1,833
+136
+8% +$95.6K ﹤0.01% 1917
2019
Q1 		$1.2M Buy
1,697
+55
+3% +$32.9K ﹤0.01% 1973
2018
Q4 		$768K Buy
1,642
+84
+5% +$54.2K ﹤0.01% 2146
2018
Q3 		$1.34M Buy
1,558
+233
+18% +$168K ﹤0.01% 1975
2018
Q2 		$913K Hold
1,325
– – ﹤0.01% 2223
2018
Q1 		$591K Buy
1,325
+150
+13% +$72.8K ﹤0.01% 2323
2017
Q4 		$518K Hold
1,175
– – ﹤0.01% 2401
2017
Q3 		$579K Hold
1,175
– – ﹤0.01% 2333
2017
Q2 		$651K Buy
+1,175
New +$746K ﹤0.01% 2318
2016
Q2 		– Sell
-836
Closed -$182K – 2610
2016
Q1 		$182K Buy
836
+139
+20% +$41.5K ﹤0.01% 2567
2015
Q4 		$423K Buy
+697
New +$383K ﹤0.01% 2354

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank's TVRD Position: Q2 2023 in Review

Swiss National Bank sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 2,739 shares — an estimated $484K sold.

Swiss National Bank first reported a position in TVRD in Q4 2015 and held it in 26 quarters. The position peaked at $2.35M in Q1 2021. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Swiss National Bank reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 2,739 Tvardi Therapeutics shares in Q2 2023, an estimated $484K.
  • Swiss National Bank first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 26 quarters.
  • Swiss National Bank's Tvardi Therapeutics position peaked at $2.35M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.